Skip to main content
SpringerLink
Log in

Analysis of daily teriparatide treatment for osteoporosis in men

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

An Erratum to this article was published on 20 June 2015

Abstract

Summary

The percent and absolute lumbar spine and femoral neck bone mineral densities and absolute procollagen type I N-terminal propeptide (PINP) increases following a 20-μg/day teriparatide treatment for 12 months were similar in men and women regardless of sex differences.

Introduction

Several placebo-controlled studies have measured the effects of daily teriparatide in men and postmenopausal women with osteoporosis but none have directly compared the effects between these groups. We retrospectively compared the effects of daily teriparatide therapy in men and postmenopausal women with osteoporosis and investigated biochemical markers of bone turnover to detect possible sex differences.

Methods

Patients (563; 75 men and 488 women) with osteoporosis were retrospectively investigated. All patients were administered with teriparatide at 20 μg/day for 12 months. The primary efficacy measure was changed in lumbar spine (LS) and femoral neck (FN) bone mineral density (BMD) after 12 months of treatment. The change in serum levels of procollagen type I N-terminal propeptide (PINP) and urinary N-telopeptide (uNTX) excretion after 4, 8 and 12 months of treatment were also measured.

Results

In men, the percent LS BMD significantly increased by 11.3 ± 9.9 % (mean ± standard deviation (SD)) and the FN BMD increased by 0.4 ± 6.4 % without a significant difference at 12 months. In postmenopausal women, the percent LS BMD significantly increased by 9.6 ± 8.1 % and the FN BMD significantly increased by 2.4 ± 7.8 % at 12 months. The percent and absolute BMD increases in LS and FN between men and women were similar. The absolute increases in PINP were similar in both groups at 4, 8 and 12 months. However, the absolute increases in uNTX were significantly lower in men than in women at 8 and 12 months.

Conclusion

Daily teriparatide treatment was as effective in men as in postmenopausal women regardless of sex differences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413

    Article  CAS  PubMed  Google Scholar 

  2. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 30:513–521

    Article  Google Scholar 

  3. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS, Endocrine Society (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822

    Article  CAS  PubMed  Google Scholar 

  4. Olszynski WP, Davison KS (2008) Alendronate for the treatment of osteoporosis in men. Expert Opin Pharmacother 9:491–498

    Article  CAS  PubMed  Google Scholar 

  5. Mullender MG, Tan SD, Vico L, Alexandre C, Klein-Nulend J (2005) Differences in osteocyte density and bone histomorphometry between men and women and between healthy and osteoporotic subjects. Calcif Tissue Int 77:291–296

    Article  CAS  PubMed  Google Scholar 

  6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  7. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  CAS  PubMed  Google Scholar 

  8. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076

    CAS  PubMed  Google Scholar 

  9. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502

    Article  CAS  PubMed  Google Scholar 

  10. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Nakamura T, Kono T, Sudo A (2014) An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int 25:337–384

    Google Scholar 

  11. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  CAS  PubMed  Google Scholar 

  12. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A (2014) Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis. Bone 66C:26–30

    Article  Google Scholar 

  13. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A (2014) Cortical thickness of the femur and long-term bisphosphonate use. J Bone Miner Res. doi:10.1002/jbmr.2345

    Google Scholar 

  14. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104

    Article  CAS  PubMed  Google Scholar 

  15. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23

    Article  CAS  PubMed  Google Scholar 

  16. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM (2006) Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882–2887

    Article  CAS  PubMed  Google Scholar 

  17. Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28:1355–1368

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Koji Fukuda, Hideki Ito, Takeshi Kato, Kana Nakanishi, Kenji Kuroda, Haruyoshi Mizuno, Yohei Takigawa, Yoshifumi Takahashi and Hiroaki Takeuchi for their diligence in preparing the clinical recordings. The authors thank Dr. Hideki Yamamoto and Dr. Takahito Saito for their cooperation to osteoporosis treatment. The authors acknowledge Akiko Mizutani and Nobuyuki Tanaka for their assistance.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Tomidahama Hospital, 26-14, Tomidahamacho, Yokkaichi, Mie, 510-8008, Japan

    R. Niimi, T. Kono, A. Nishihara & T. Kono

  2. Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan

    M. Hasegawa, A. Matsumine & A. Sudo

Authors
  1. R. Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Kono
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Nishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Matsumine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Kono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Sudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Niimi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niimi, R., Kono, T., Nishihara, A. et al. Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int 26, 1303–1309 (2015). https://doi.org/10.1007/s00198-014-3001-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-3001-1

Keywords

Search

Navigation